EdgarLookup

SUNHYDROGEN, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that SUNHYDROGEN, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-21.7%
Return on Assets
Net income ÷ assets
0.02x
Debt-to-Equity
Total liabilities ÷ equity

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($8.23M) Sep 15, 2025
FY2025 Jun 30, 2024 ($9.88M) Sep 15, 2025
FY2024 Jun 30, 2023 $975.0K Sep 30, 2024
FY2023 Jun 30, 2022 $90.03M Sep 29, 2023
FY2022 Jun 30, 2021 ($81.50M) Oct 7, 2022
FY2021 Jun 30, 2020 ($57.53M) Oct 8, 2021
FY2020 Jun 30, 2019 $3.98M Sep 23, 2020
FY2019 Jun 30, 2018 ($10.20M) Sep 30, 2019
FY2018 Jun 30, 2017 $2.24M Sep 25, 2018
FY2017 Jun 30, 2016 $6.04M Sep 21, 2017

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($5.82M) Sep 15, 2025
FY2025 Jun 30, 2024 ($5.00M) Sep 15, 2025
FY2024 Jun 30, 2023 ($9.27M) Sep 30, 2024
FY2023 Jun 30, 2022 ($4.48M) Sep 29, 2023
FY2022 Jun 30, 2021 ($5.81M) Oct 7, 2022
FY2021 Jun 30, 2020 ($1.68M) Oct 8, 2021
FY2020 Jun 30, 2019 ($1.83M) Sep 23, 2020
FY2019 Jun 30, 2018 ($750.8K) Sep 30, 2019
FY2018 Jun 30, 2017 ($602.2K) Sep 25, 2018
FY2017 Jun 30, 2016 ($481.3K) Sep 21, 2017

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $3.44M Sep 15, 2025
FY2025 Jun 30, 2024 $2.57M Sep 15, 2025
FY2024 Jun 30, 2023 $3.44M Sep 30, 2024
FY2023 Jun 30, 2022 $1.79M Sep 29, 2023
FY2022 Jun 30, 2021 $2.00M Oct 7, 2022
FY2021 Jun 30, 2020 $615.7K Oct 8, 2021
FY2020 Jun 30, 2019 $528.9K Sep 23, 2020
FY2019 Jun 30, 2018 $245.7K Sep 30, 2019
FY2018 Jun 30, 2017 $140.3K Sep 25, 2018
FY2017 Jun 30, 2016 $12.1K Sep 21, 2017

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($3.65M) Sep 15, 2025
FY2025 Jun 30, 2024 ($1.84M) Sep 15, 2025
FY2024 Jun 30, 2023 ($4.26M) Sep 30, 2024
FY2023 Jun 30, 2022 ($3.44M) Sep 29, 2023
FY2022 Jun 30, 2021 ($5.38M) Oct 7, 2022
FY2021 Jun 30, 2020 ($695.8K) Oct 8, 2021
FY2020 Jun 30, 2019 ($853.7K) Sep 23, 2020
FY2019 Jun 30, 2018 ($708.8K) Sep 30, 2019
FY2018 Jun 30, 2017 ($573.3K) Sep 25, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $17.0K Sep 15, 2025
FY2025 Jun 30, 2024 $23.3K Sep 15, 2025
FY2024 Jun 30, 2023 $33.8K Sep 30, 2024
FY2022 Jun 30, 2021 $213.9K Oct 7, 2022
FY2021 Jun 30, 2020 $780 Oct 8, 2021
FY2020 Jun 30, 2019 $13.1K Sep 23, 2020
FY2019 Jun 30, 2018 $1.9K Sep 30, 2019
FY2015 Jun 30, 2014 $2.0K Sep 28, 2015
FY2013 Jun 30, 2013 $4.2K Oct 31, 2013
FY2012 Jun 30, 2012 $4.2K Sep 28, 2012

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $37.92M Sep 15, 2025
FY2025 Jun 30, 2024 $43.37M Sep 15, 2025
FY2024 Jun 30, 2023 $51.21M Sep 30, 2024
FY2023 Jun 30, 2022 $52.21M Sep 29, 2023
FY2022 Jun 30, 2021 $56.24M Oct 7, 2022
FY2021 Jun 30, 2020 $291.8K Oct 8, 2021
FY2020 Jun 30, 2019 $150.6K Sep 23, 2020
FY2019 Jun 30, 2018 $196.6K Sep 30, 2019
FY2018 Jun 30, 2017 $165.8K Sep 25, 2018
FY2017 Jun 30, 2016 $160.5K Sep 21, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $674.9K Sep 15, 2025
FY2025 Jun 30, 2024 $759.5K Sep 15, 2025
FY2024 Jun 30, 2023 $377.0K Sep 30, 2024
FY2023 Jun 30, 2022 $27.31M Sep 29, 2023
FY2022 Jun 30, 2021 $136.81M Oct 7, 2022
FY2021 Jun 30, 2020 $62.12M Oct 8, 2021
FY2020 Jun 30, 2019 $6.66M Sep 23, 2020
FY2019 Jun 30, 2018 $13.21M Sep 30, 2019
FY2018 Jun 30, 2017 $4.42M Sep 25, 2018
FY2017 Jun 30, 2016 $7.96M Sep 21, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $36.58M Sep 15, 2025
FY2025 Jun 30, 2024 $41.72M Sep 15, 2025
FY2025 Jun 30, 2023 $49.74M Sep 15, 2025
FY2024 Jun 30, 2022 $24.64M Sep 30, 2024
FY2023 Jun 30, 2021 ($80.57M) Sep 29, 2023
FY2022 Jun 30, 2020 ($61.83M) Oct 7, 2022
FY2021 Jun 30, 2019 ($6.51M) Oct 8, 2021
FY2020 Jun 30, 2018 ($13.02M) Sep 23, 2020
FY2019 Jun 30, 2017 ($4.25M) Sep 30, 2019
FY2018 Jun 30, 2016 ($7.80M) Sep 25, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($100.08M) Sep 15, 2025
FY2025 Jun 30, 2024 ($91.85M) Sep 15, 2025
FY2024 Jun 30, 2023 ($81.97M) Sep 30, 2024
FY2023 Jun 30, 2022 ($82.95M) Sep 29, 2023
FY2022 Jun 30, 2021 ($172.98M) Oct 7, 2022
FY2021 Jun 30, 2020 ($75.55M) Oct 8, 2021
FY2020 Jun 30, 2019 ($18.02M) Sep 23, 2020
FY2019 Jun 30, 2018 ($22.00M) Sep 30, 2019
FY2018 Jun 30, 2017 ($11.80M) Sep 25, 2018
FY2017 Jun 30, 2016 ($14.04M) Sep 21, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $34.63M Sep 15, 2025
FY2025 Jun 30, 2024 $39.04M Sep 15, 2025
FY2024 Jun 30, 2023 $37.19M Sep 30, 2024
FY2023 Jun 30, 2022 $27.68M Sep 29, 2023
FY2022 Jun 30, 2021 $56.01M Oct 7, 2022
FY2021 Jun 30, 2020 $195.0K Oct 8, 2021
FY2021 Jun 30, 2019 $35.1K Oct 8, 2021
FY2020 Jun 30, 2018 $97.3K Sep 23, 2020
FY2019 Jun 30, 2017 $80.1K Sep 30, 2019
FY2018 Jun 30, 2016 $119.9K Sep 25, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2022 Jun 30, 2022 $827.5K Oct 7, 2022
FY2021 Jun 30, 2021 $1.27M Oct 8, 2021

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Sep 15, 2025
FY2025 Jun 30, 2024 0 Sep 15, 2025
FY2024 Jun 30, 2023 0 Sep 30, 2024
FY2023 Jun 30, 2022 0 Sep 29, 2023
FY2022 Jun 30, 2021 0 Oct 7, 2022
FY2018 Jun 30, 2018 0 Sep 25, 2018
FY2018 Jun 30, 2017 0 Sep 25, 2018
FY2017 Jun 30, 2016 0 Sep 21, 2017
FY2016 Jun 30, 2015 0 Sep 21, 2016

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Sep 15, 2025
FY2025 Jun 30, 2024 0 Sep 15, 2025
FY2023 Jun 30, 2023 0 Sep 29, 2023
FY2023 Jun 30, 2022 0 Sep 29, 2023
FY2022 Jun 30, 2021 0 Oct 7, 2022
FY2018 Jun 30, 2018 0 Sep 25, 2018
FY2018 Jun 30, 2017 0 Sep 25, 2018
FY2017 Jun 30, 2016 0 Sep 21, 2017
FY2016 Jun 30, 2015 0 Sep 21, 2016

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 5.44B Sep 15, 2025
FY2025 Jun 30, 2024 5.09B Sep 15, 2025
FY2024 Jun 30, 2023 4.82B Sep 30, 2024
FY2023 Jun 30, 2022 4.27B Sep 29, 2023
FY2022 Jun 30, 2021 3.85B Oct 7, 2022
FY2021 Jun 30, 2020 2.05B Oct 8, 2021
FY2020 Jun 30, 2019 1.08B Sep 23, 2020
FY2019 Jun 30, 2018 852.46M Sep 30, 2019
FY2018 Jun 30, 2017 699.48M Sep 25, 2018
FY2017 Jun 30, 2016 589.55M Sep 21, 2017